NRX Pharmaceuticals, Inc. — Director's Dealing 2021

May 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NRX Pharmaceuticals, Inc. (BRPA)
CIK: 0001719406
Period of Report: 2021-05-24

Reporting Person: Big Rock Partners Sponsor, LLC (10% Owner)
Reporting Person: ACKERMAN RICHARD (Director, President & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Stock	D	5435	—	Disposed	492065	Indirect
2021-05-24	Common Stock	C	27250	—	Acquired	519315	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-24	Rights, exchangeable for Common Stock	$	C	272500	Disposed		Common Stock (27250)	Indirect
2021-05-24	Unit Purchase Option	$10	P	100000	Acquired	2022-11-20	Common Stock (160000)	Indirect

Footnotes

F1: Mr. Ackerman is the managing member of this entity and has the sole voting and dispositive power of the securities held thereby. Accordingly, Mr. Ackerman may be deemed to have beneficial ownership of such shares. Mr. Ackerman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F2: Each of the Issuer's Rights were convertible into 1/10 of one share of the Issuer's common stock upon consummation of the Issuer's initial business combination and had no expiration
date. In connection with the Issuer's business combination, such Rights automatically converted into shares of common stock.

F3: Mr. Ackerman is the majority owner of this entity and may be deemed to have beneficial ownership of the shares owned thereby. Mr. Ackerman disclaims beneficial ownership except to the extent of his pecuniary interest therein.